Sihuan Pharmaceutical Secures CFDA pproval for Imigliptin DihydrochloridePhase I...

Hong Kong, 28 July, 2016- Sihuan Pharmaceutical Holdings Group Ltd. announced that Imigliptin Dihydrochloride received the approval for Phase II/III clinical trials from China Food and Drug Administra...

Sihuan Pharmaceutical Secures CFDA pproval for Imigliptin DihydrochloridePhase II/III Clinical Trials
2016-12-15
CFDA Granted Approval forPhase I/II/III Clinical Trials of Sihuan Pharmaceutical’s Internally Developed Innovative Pate

CFDA Granted Approval forPhase I/II/III Clinical Trials of Sihuan Pharmaceutical’s Internally Developed Innovative Patented New Drug – FadanafilHONG KONG, 14 December 2016, – Sihuan Pharmaceutical ...

2016-11-01
Successful listing of LIDE Biotech, invested by Sihuan Pharmaceutical in form of equity participation

Successful listing of LIDE Biotech, invested by Sihuan Pharmaceutical in form of equity participation

2016-09-27
Sihuan Pharmaceutical Secures CFDA pproval for Imigliptin DihydrochloridePhase II/III Clinical Trials

Hong Kong, 28 July, 2016- Sihuan Pharmaceutical Holdings Group Ltd. announced that Imigliptin Dihydrochloride received the approval for Phase II/III clinical trials from China Food and Drug Administra...

2015-12-24
ShandongXuanZhu Entered into Innovative Research Collaboration with Institute of Immunology of Tsinghua University

Recently,Shandong XuanZhu Pharma Co., Ltd. (“XuanZhu”), a wholly-owned subsidiary of the Group, and the ImmunologyInstitute ofTsinghua University, entered into a novel flexiblecollaboration agreemen...

2015-12-23
ShandongXuanZhu Entered into Innovative Research Collaboration with Institute of Immunology of Tsinghua University

Recently,Shandong XuanZhu Pharma Co., Ltd. (“XuanZhu”), a wholly-owned subsidiary of the Group, and the ImmunologyInstitute ofTsinghua University, entered into a novel flexiblecollaboration agreemen...

Total 11 Pages  First page  Page up  Page down  Last page

Select

  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012